Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the ten analysts that are covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $23.00.
AMRX has been the topic of a number of analyst reports. Oppenheimer began coverage on shares of Amneal Pharmaceuticals in a report on Wednesday, September 23rd. They issued an “outperform” rating and a $27.00 price objective on the stock. Zacks Research raised shares of Amneal Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, October 26th. The Goldman Sachs Group restated a “buy” rating and issued a $24.00 target price on shares of Amneal Pharmaceuticals in a research report on Thursday, October 29th. JPMorgan Chase & Co. upped their target price on shares of Amneal Pharmaceuticals from $24.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 4th. Finally, Barclays raised their price target on shares of Amneal Pharmaceuticals from $16.00 to $20.00 and gave the company an “overweight” rating in a research note on Thursday, September 17th.
Check Out Our Latest Research Report on AMRX
Amneal Pharmaceuticals Stock Performance
Shares of AMRX stock opened at $21.11 on Friday. The stock has a market capitalization of $7.36 billion, a price-to-earnings ratio of 50.27, a PEG ratio of 2.40 and a beta of 1.24. Amneal Pharmaceuticals has a one year low of $11.50 and a one year high of $22.13. The company’s 50-day simple moving average is $20.13 and its 200-day simple moving average is $16.29. The company has a debt-to-equity ratio of 5.61, a quick ratio of 1.24 and a current ratio of 1.87.
Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) last released its earnings results on Tuesday, November 3rd. The company reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of $0.23 by $0.03. Amneal Pharmaceuticals had a return on equity of 283.50% and a net margin of 4.17%. The company had revenue of $862.68 million for the quarter. Equities analysts anticipate that Amneal Pharmaceuticals will post 0.98 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Amneal Pharmaceuticals
Hedge funds have recently modified their holdings of the company. Paralel Advisors LLC acquired a new stake in shares of Amneal Pharmaceuticals during the 2nd quarter valued at $3,217,000. California State Teachers Retirement System lifted its holdings in shares of Amneal Pharmaceuticals by 37.6% during the first quarter. California State Teachers Retirement System now owns 207,239 shares of the company’s stock valued at $2,576,000 after purchasing an additional 56,588 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of Amneal Pharmaceuticals by 1,586.8% in the 1st quarter. Renaissance Technologies LLC now owns 276,637 shares of the company’s stock valued at $3,439,000 after purchasing an additional 260,237 shares during the period. Congress Asset Management Co. boosted its position in shares of Amneal Pharmaceuticals by 94.7% in the 3rd quarter. Congress Asset Management Co. now owns 1,524,355 shares of the company’s stock valued at $30,701,000 after purchasing an additional 741,577 shares during the period. Finally, Diversify Advisory Services LLC increased its stake in Amneal Pharmaceuticals by 572.1% in the 3rd quarter. Diversify Advisory Services LLC now owns 119,275 shares of the company’s stock worth $2,296,000 after purchasing an additional 101,529 shares in the last quarter. 31.82% of the stock is currently owned by institutional investors and hedge funds.
About Amneal Pharmaceuticals
Amneal Pharmaceuticals is a U.S.-based pharmaceutical company that develops, manufactures and markets generic and specialty medicines. Its products include a broad range of generic drugs, including complex formulations and injectable medicines, as well as branded therapies in areas such as neurology and endocrinology. The company also operates AvKARE, which distributes pharmaceuticals and medical products to government, institutional and commercial customers. Amneal serves customers in the United States and in international markets.
Featured Articles
- Five stocks we like better than Amneal Pharmaceuticals
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
